Added to YB: 2026-01-15
Pitch date: 2026-01-13
MRNA [bullish]
Moderna, Inc.
+2.14%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$13.2B
Pitch Price
$39.73
Price Target
100.00 (+146%)
Dividend
N/A
EV/EBITDA
-2.33
P/E
-4.20
EV/Sales
3.27
Sector
Biotechnology
Category
growth
Alpha Talon Investment Research Analysis of the 44th Annual J.P.Morgan Healthcare Conference - Moderna, Inc.
MRNA (update): 2025 rev $1.9B above guidance, slashed costs from $6.3B to $4.3-4.5B (targeting $3.5-3.9B by 2027), cash breakeven by 2028. $8.1B cash provides runway. Seasonal vaccine franchise expanding to 6 products by 2028. Europe reopens 2027 ($1.75B market). Dense oncology pipeline w/ Merck, Phase III data 2026+. Alpha Talon bull target $100 by 2030.
Read full article (4 min)